Including Autistic Adults in Clinical Research - Why is it Important?
Adults on the Autistic Spectrum often face significant physical and mental health challenges, yet they are still underrepresented in clinical trials. This situation leaves us with very few randomized controlled trials (RCTs) that can guide treatment for conditions like anxiety, which is common among autistic people.
A study published in Autism, 2026 Sep, examined a crucial aspect of participation in medical research. It was conducted as part of a larger study called STRATA, which aims to evaluate the effectiveness of the drug sertraline (an SSRI) in reducing anxiety in autistic adults. The researchers anticipated challenges in recruiting and retaining participants for this type of study, and therefore incorporated qualitative research to support the process and examine the acceptability of participation.
What Was Examined and How?
The qualitative study aimed to better understand what helps or hinders autistic people from joining and staying in clinical trials. The researchers used the Theoretical Framework of Acceptability (TFA) to assess the acceptability of the study's design and execution for autistic adults. The study involved 64 interviews with autistic adults at various stages of the STRATA trial, including two who chose not to participate. Data were analyzed thematically and mapped to the seven components of the TFA framework, which examine participants' feelings about the trial, the effort required, alignment with their personal values, their understanding of the research, potential compromises, potential benefits, and their self-confidence in their ability to participate.
Key Findings and Their Significance
The study's findings indicate that most participants viewed participation in a double-blind drug trial as acceptable across all TFA domains. They considered different aspects of acceptability differently when referring to their expectations versus their actual experiences during participation. The study found that STRATA was perceived by most participants as a low-burden, scientifically ethical, and methodologically coherent study. Participants reported minimal compromises, saw potential for benefits, and noted a sense of self-efficacy in managing anxiety and participating in the research.
These findings highlight that the acceptability of participation in clinical trials is a dynamic and multidimensional process. The study points to ways in which acceptability can be improved: through meaningful involvement of autistic people at all stages of the research cycle, by designing accessible and clear information for participants, and through attentive and continuous communication and engagement. These approaches, adopted in the STRATA study, can contribute significantly to building trust and ensuring that clinical trials indeed meet the needs of adults on the Autistic Spectrum.
Limitation and Future Recommendation
It is important to remember that this qualitative study offers deep insights into participants' experiences and perceptions, but the acceptability of participation may vary from person to person and over time. The understanding that acceptability is dynamic and multidimensional emphasizes the need for continuous adaptation of research approaches to ensure optimal inclusion of the autistic community.